Supplementary Data — Propolis for COVID-19: real-time meta analysis of 3 studies

@CovidAnalysis, November 2025, Version 3V3
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ BeeCovid Silveira (RCT) 62% 0.38 [0.11-1.31] ventilation 3/41 8/41 Improvement, RR [CI] Treatment Control BeeCovid Silveira (RCT) 73% 0.27 [0.06-1.19] ventilation 2/38 8/41 BeeCovid Silveira (RCT) 24% 0.76 [0.27-2.15] ICU 5/24 6/22 BeeCovid Silveira (RCT) 93% 0.07 [0.01-0.45] ICU 0/27 6/22 BeeCovid Silveira (RCT) 35% 0.65 [0.50-0.85] hosp. time 42 (n) 42 (n) BeeCovid Silveira (RCT) 25% 0.75 [0.57-1.00] hosp. time 40 (n) 42 (n) BeeCovid2 Silveira (DB RCT) 22% 0.78 [0.34-1.66] ventilation 10/98 12/90 BeeCovid2 Silveira (DB RCT) 11% 0.89 [0.52-1.41] ICU 23/97 24/89 BeeCovid2 Silveira (DB RCT) 16% 0.84 [0.64-1.09] hosp. time 98 (n) 90 (n) BeeCovid2 Silveira (DB RCT) 68% 0.32 [0.12-0.80] misc. 6/98 17/90 BeeCovid2 Silveira (DB RCT) 25% 0.75 [0.36-1.43] misc. 13/98 16/90 Kosari (DB RCT) 86% 0.14 [0.01-2.72] death 0/70 3/70 CT​1​ Kosari (DB RCT) 86% 0.14 [0.02-1.13] ICU 1/70 7/70 CT​1​ Kosari (DB RCT) 64% 0.36 [0.17-0.76] no recov. 8/70 22/70 CT​1​ Propolis COVID-19 outcomes c19early.org November 2025 ​1​ CT: study uses combined treatment Favors propolis Favors control
Fig. S1. All outcomes.